Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium

医学 临床试验 微生物群 生物技术 业务 重症监护医学 生物信息学 病理 生物
作者
Ching‐Hung Tseng,Sunny H. Wong,Jun Yu,Yeong Yeh Lee,Jun Terauchi,Hsin‐Chih Lai,Jiing‐Chyuan Luo,Cheng‐Yen Kao,Sung‐Liang Yu,Jyh‐Ming Liou,Deng‐Chyang Wu,Ming‐Chih Hou,Ming-Shiang Wu,Jiunn‐Jong Wu,Joseph J.�Y. Sung,Emad El‐Omar,Chun‐Ying Wu
出处
期刊:Gut [BMJ]
卷期号:74 (5): 706-713 被引量:13
标识
DOI:10.1136/gutjnl-2024-334501
摘要

Objective Live biotherapeutic products (LBPs) are biological products composed of living micro-organisms, developed to prevent, treat, or cure diseases. Examples include cultured strains of Akkermansia muciniphila and Christensenella minuta , as well as treatments using purified Firmicutes spores for recurrent Clostridioides difficile infections. There is a need for guidelines over the increasing interest in developing LBPs. A panel of microbiome experts from Asia-Pacific countries articulates their perspectives on key considerations for LBP development. Design Experts in microbiome research, microbiology, gastroenterology, internal medicine and biotherapeutics industry were invited to form a panel. During the 2023 Inauguration Conference of the Asia-Pacific Microbiota Consortium, an organised, iterative roundtable discussion was conducted to build expert consensus on critical issues surrounding the development of LBP. Results The consensus statements were organised into three main aspects: (a) rationales of LBP development, (b) preclinical studies and (c) preparation for clinical studies. The panel strongly recommended to prioritise human-derived and food-sourced strains for development, with indications based on clinical need and efficacy shown in studies. Preclinical evaluation should involve thorough screening, genotyping and phenotyping, as well as comprehensive in vitro and animal studies to assess functional mechanisms and microbiological safety. Rigorous cell banking practices and genetic monitoring are essential to ensure product consistency and safety throughout the manufacturing process. Clinical trials, including postmarketing surveillance, must be carefully designed and closely monitored, with robust safety and risk management protocols in place. Conclusions The development of LBP should be approached with a strong emphasis on microbiological evaluation, clinical relevance, scientific mechanisms and safety at every stage. These measures are essential to ensure the safety, effectiveness and long-term success of the product.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
3秒前
无一发布了新的文献求助10
3秒前
领导范儿应助木启采纳,获得30
4秒前
正直忆秋发布了新的文献求助10
4秒前
红豆泥完成签到,获得积分10
4秒前
Yara.H发布了新的文献求助10
4秒前
炙热从蕾完成签到,获得积分10
5秒前
5秒前
7秒前
炙热从蕾发布了新的文献求助10
7秒前
Oyama完成签到,获得积分10
8秒前
十块就好完成签到,获得积分10
9秒前
要减肥鸣凤完成签到,获得积分10
9秒前
小满发布了新的文献求助10
10秒前
豚豚完成签到,获得积分10
10秒前
北听筠应助科研通管家采纳,获得10
11秒前
晚安应助科研通管家采纳,获得10
11秒前
Twonej应助科研通管家采纳,获得30
11秒前
zwj发布了新的文献求助10
11秒前
11秒前
11秒前
Twonej应助科研通管家采纳,获得30
11秒前
11秒前
12秒前
12秒前
12秒前
12秒前
12秒前
13秒前
典雅的如之完成签到,获得积分10
13秒前
形成发布了新的文献求助10
13秒前
不懈奋进应助现代白玉采纳,获得30
14秒前
生动的友卉完成签到,获得积分20
14秒前
丘比特应助Yara.H采纳,获得10
16秒前
俊逸语风发布了新的文献求助10
17秒前
宜醉宜游宜睡应助小蚂蚁采纳,获得10
17秒前
WJY完成签到 ,获得积分10
17秒前
18秒前
18秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Arthritis and Related Conditions, An Issue of Orthopedic Clinics 1000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7287753
求助须知:如何正确求助?哪些是违规求助? 8907489
关于积分的说明 18851617
捐赠科研通 6956514
什么是DOI,文献DOI怎么找? 3208711
关于科研通互助平台的介绍 2378546
邀请新用户注册赠送积分活动 2184481